异烟肼联合莫西沙星对耐药性肺结核患者临床疗效及炎症因子的影响  

The Clinical Efficacy of Isoniazid Combined with Moxifloxacin in Drug⁃Re⁃sistant Pulmonary Tuberculosis Patients and Its Impact on Inflammatory Factors

作　　者：李继翰 国美峰 倪磊磊 张新园 王桂芹 荣立萍 LI Jihan;GUO Meifeng;NI Leilei;ZHANG Xinyuan;WANG Guiqin;RONG Liping(The Second Department of Tuberculosis,the Third Hospital of Cangzhou,Cangzhou,Hebei 061000,China;Department of Tuberculosis,the Third Hospital of Cangzhou,Cangzhou,Hebei 061000,China)

机构地区：[1]沧州市第三医院结核二科,河北沧州061000 [2]沧州市第三医院结核三科,河北沧州061000

出　　处：《转化医学杂志》2024年第7期1136-1140,共5页Translational Medicine Journal

基　　金：2023年度河北省中医药管理局中医药类科学研究课题计划项目(2023272)。

摘　　要：目的探讨异烟肼联合莫西沙星对耐药性肺结核患者的临床疗效及炎症因子的影响。方法回顾性选取2022年1月至2024年1月在沧州市第三医院接受治疗的120例耐药性肺结核患者的病历资料,根据不同给药方法将患者分为对照组58例和观察组62例。对照组给予异烟肼治疗,观察组在对照组的基础上联合莫西沙星治疗。比较2组患者的临床疗效、肺部病变恢复情况、炎症因子水平及免疫细胞水平变化。结果观察组治疗有效率为95.16%,显著高于对照组的82.76%,差异有统计学意义(P<0.05)。观察组痰菌转阴率、病灶吸收率及空洞闭合率均显著高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组肿瘤坏死因子α、血清降钙素原和C反应蛋白水平显著低于对照组(P<0.05),CD4+T细胞水平高于对照组,CD8+T细胞水平低于对照组,差异均有统计学意义(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论异烟肼联合莫西沙星对耐药性肺结核患者的治疗具有良好疗效,能够有效改善患者的炎症反应,且安全性较高。Objective This study aims to evaluate the clinical efficacy of isoniazid combined with moxifloxacin in the treatment of drug⁃resistant pulmonary tuberculosis patients and its effects on inflammatory factors.Methods A retrospective analysis was conducted on the medical records of 120 drug⁃resistant pulmonary tuberculosis patients treated at Cangzhou Third Hospital from January 2022 to January 2024.The patients were divided into two groups:a control group(58 cases)and an observation group(62 cases).The control group was treated with isoniazid,while the observation group received a combina⁃tion therapy of isoniazid and moxifloxacin.Clinical efficacy,pulmonary lesion recovery,levels of inflammatory factors,and changes in immune cell levels were compared between the two groups.Results The treatment effectiveness rate in the obser⁃vation group was 95.16%,significantly higher than the 82.76%in the control group(P<0.05).Furthermore,the sputum conversion rate,lesion absorption rate,and cavity closure rate in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the levels of TNF⁃α,CRP,and PCT in the observation group were significant⁃ly lower than in the control group(P<0.05),while CD4+levels were higher and CD8+levels were lower in the observation group compared to the control group(P<0.05).The incidence of adverse reactions showed no significant difference between the two groups(P>0.05).Conclusion Isoniazid combined with moxifloxacin provides excellent therapeutic efficacy in the treatment of drug⁃resistant pulmonary tuberculosis,effectively reducing inflammatory response,with a high safety profile.

关 键 词：耐药性肺结核 异烟肼 莫西沙星 炎症因子 临床疗效 

分 类 号：R521[医药卫生—内科学]